These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15970795)

  • 1. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.
    Tai G; Farin F; Rieder MJ; Dreisbach AW; Veenstra DL; Verlinde CL; Rettie AE
    Pharmacogenet Genomics; 2005 Jul; 15(7):475-81. PubMed ID: 15970795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
    Takahashi H; Wilkinson GR; Caraco Y; Muszkat M; Kim RB; Kashima T; Kimura S; Echizen H
    Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.
    Takahashi H; Ieiri I; Wilkinson GR; Mayo G; Kashima T; Kimura S; Otsubo K; Echizen H
    Blood; 2004 Apr; 103(8):3055-7. PubMed ID: 15070684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
    Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
    Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
    Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
    Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
    King BP; Khan TI; Aithal GP; Kamali F; Daly AK
    Pharmacogenetics; 2004 Dec; 14(12):813-22. PubMed ID: 15608560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.
    O'Brien TJ; Kidd RS; Richard CA; Ha NH; Witcher P; Tran LV; Barbour A; Tuck M; McIntosh SD; Douglas JN; Harralson AF
    Clin Chim Acta; 2013 Sep; 424():73-5. PubMed ID: 23688605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9.
    Lee SY; Kim JS; Kim JW
    Yonsei Med J; 2005 Dec; 46(6):843-6. PubMed ID: 16385662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.
    Lindh JD; Holm L; Andersson ML; Rane A
    Eur J Clin Pharmacol; 2009 Apr; 65(4):365-75. PubMed ID: 19031075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
    Lu Y; Yang J; Zhang H; Yang J
    Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose.
    Tanira MO; Al-Mukhaini MK; Al-Hinai AT; Al Balushi KA; Ahmed IS
    Community Genet; 2007; 10(1):32-7. PubMed ID: 17167248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
    Crespi CL; Miller VP
    Pharmacogenetics; 1997 Jun; 7(3):203-10. PubMed ID: 9241660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.